Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data

Author： Nyberg Fredrik   Barratt Bryan J   Mushiroda Taisei   Takahashi Atsushi   Jawaid Ansar   Hada Shuji   Umemura Takaaki   Fukuoka Masahiro   Nakata Koichiro   Ohe Yuichiro   Kato Harubumi   Kudoh Shoji   March Ruth   Nakamura Yusuke   Kamatani Naoyuki  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.7, 2011-07, pp. : 965-975

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

The role of gefitinib in the management of Asian patients with non-small cell lung cancer

By Chang Alex Y  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 401-411

Informa Healthcare

Access to resources Recommend Favorite

Gefitinib in non-small cell lung cancer

By Tamura Kenji   Fukuoka Masahiro  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 985-993

Informa Healthcare

Access to resources Recommend Favorite

Gefitinib: Interstitial pneumonia in a patient with non-small cell lung cancer: case report

By  

Reactions Weekly, Vol. 1, Iss. 1057, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite